Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
This patent grant strengthens Greenland Mines’ position in the rapidly evolving field of gene therapy for neurodegenerative conditions, which affect millions worldwide. The Klotho protein, known for its role in aging and cognitive function, offers a novel approach to treating diseases that currently have limited therapeutic options. The company’s biotech division focuses on developing KLTO-202 as a primary indication for ALS, a progressive neurodegenerative disease with a high unmet medical need. The advancement of KLTO-202 to GMP manufacturing marks a significant step toward clinical trials, as regulatory-grade production is essential for human testing.
Greenland Mines operates two divisions: mining, focused on the Skaergaard Project in Greenland and the Sarfartoq rare earths project, and biotech, which includes the Klotho gene therapy programs. The company’s strategy centers on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and midstream processing opportunities, while advancing its North Atlantic Critical Metals Corridor vision. The biotech division’s progress, however, is independent of the mining operations and represents a distinct value driver for shareholders.
The patent news underscores the importance of intellectual property in biotechnology, where exclusive rights can provide a competitive advantage and attract partnerships or investment. For patients and the medical community, the development of Klotho-based therapies holds promise for slowing or halting the progression of debilitating neurological diseases. However, the company cautions that forward-looking statements involve risks and uncertainties, and actual results may differ materially from expectations. Investors are encouraged to review the full terms of use and disclaimers on the InvestorBrandNetwork website and the company’s filings with the SEC for a complete discussion of risk factors.
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML. The full press release can be accessed at https://ibn.fm/x2pHA.
